24-25-dihydroxyvitamin-d-3 and Osteitis-Deformans

In 15 patients suffering from Paget's disease, the serum levels of alkaline phosphatase (ALP), 25-hydroxycholecalciferol (25OHD3), 24,25-dihydroxycholecalciferol (24,25 [OH] 2D3), 1,25-dihydroxycholecalciferol (1,25 [OH] 2D3), and parathormone (PTH) as well as urinary excretion of hydroxyproline (HP) have been determined before and after three-month calcitonin therapy. Before therapy, high concentrations of serum ALP and urinary HP excretion had been observed, whereas serum levels of 24,25 (OH) 2D3 were below the lower limit of the normal range. Calcitonin therapy caused a 31% reduction in ALP and a 50% reduction in HP, as well as a significant increase in serum levels of 24,25 (OH) 2D3; the levels of 25OHD3, 1,25 (OH) 2D3, and PTH remained unchanged after treatment. The significant negative correlation between 24,25 (OH) 2D3 and ALP and HP before and after calcitonin therapy suggests that in Paget's disease there is an uncompensated increased bone usage of 24,25 (OH) 2D3.

Topics: 24,25-Dihydroxyvitamin D 3; Adult; Aged; Alkaline Phosphatase; Calcifediol; Calcitonin; Calcitriol; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteitis Deformans; Parathyroid Hormone; Time Factors; Vitamin D

We have studied the possible correlation between serum 24,25-dihydroxyvitamin D [24,25-(OH)2D] and osteocalcin levels (sBGP) in Paget's disease of bone. We measured serum calcium, phosphate, PTH, 25-hydroxyvitamin D, 1,25-(OH)2D, 24,25-(OH)2D, alkaline phosphatase (sAP), and the urinary hydroxyproline/creatinine ratio (UOH prol/creat) in 19 patients with Paget's disease of bone and 16 age- and sex-matched controls. As expected, sAP, UOH prol/creat, and sBGP levels were significantly elevated, and there was a tendency to a decrease in serum levels of 24,25-(OH)2D in Pagetic patients with respect to the control group. There was no significant difference between patients and controls in serum calcium, phosphate, PTH, 25-hydroxyvitamin D, and 1,25-(OH)2D. The Pagetic patients were subdivided into two subgroups; subgroup A had normal sBGP levels (less than 5 ng/mL), and subgroup B had increased sBGP levels (greater than 5 ng/mL). Serum 24,25-(OH)2D levels in subgroup B were significantly lower than those in controls, while subgroup A showed levels similar to those in the control group. We also found a positive linear correlation between sAP and sBGP and between sAP and UOH prol/creat as well as a negative linear correlation between sBGP and 24,25-(OH)2D and between 24,25-(OH)2D and UOH prol/creat in Pagetic patients. These results point to a possible role of 24,25-(OH)2D in disease activity.

Topics: 24,25-Dihydroxyvitamin D 3; Adult; Aged; Alkaline Phosphatase; Calcifediol; Calcitriol; Calcium; Creatinine; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteitis Deformans; Osteocalcin; Parathyroid Hormone

Topics: 24,25-Dihydroxyvitamin D 3; Bone and Bones; Humans; Osteitis Deformans; Osteocalcin

The influence of 24,25-dihydroxyvitamin D on different seric levels of osteocalcin in Paget's disease of the bone and in 11 of the control group, other parameters were also determined such as: seric levels of calcium, phosphate, parathormone, osteocalcin, 25-hydroxyvitamin D an 1,25 dihydroxyvitamin D. We observed that patients with Paget's disease showed increased or normal levels of seric osteocalcin, despite the high bone remodelling and significantly low level of 24,25-dihydroxyvitamin D observed in patients with high levels of osteocalcin. At the same time, we noticed a negative lineal correlation between both parameters. We suggest that 24,25-hydroxyvitamin D can be one of the important factors in producing increased or normal levels of osteocalcin in patients with Paget's disease of the bone.

Topics: 24,25-Dihydroxyvitamin D 3; Aged; Calcitriol; Female; Humans; Male; Middle Aged; Osteitis Deformans; Osteocalcin

We report serum 25-hydroxyvitamin D (25-OHD), 24,25-dihydroxyvitamin D [24,25-(OH)2D], and 1,25-dihydroxyvitamin D [1,25-(OH)2D] levels in untreated Paget's disease and the effect of treatment with either calcitonin (CT) or etidronate (EHDP) on these levels. In untreated Paget's patients serum 25-OHD (73 +/- 29 nmol/liter, n = 36, mean +/- SD) and 24,25-(OH)2D (0.3-12.9 nmol/liter, median 2.2, n = 36) levels were significantly lower than in age-matched controls (94 +/- 30 nmol/liter, n = 32, p less than 0.005, and 1.3-16.4 nmol/liter, median 5.3; n = 32, p less than 0.001, respectively). Also, the 24,25-(OH)2D levels correlated with the 25-OHD levels in the untreated Paget's patients (r = 0.56, p less than 0.01) and in the controls (r = 0.39, p less than 0.05). The percentage molar ratio of 24,25-(OH)2D to 25-OHD in Paget's patients had a median value of 3.7% (range 0.4-14.3%), which was not significantly different from controls, who had a median value of 5.6% (range 2.2-18%). There was no difference between the 1,25-(OH)2D, and immunoreactive PTH (iPTH) levels of Paget's patients and control subjects. The percentage molar ratio of 1,25-(OH)2D to 25-OHD in untreated Paget's patients (0.157 +/- 0.09%) was not significantly different from controls (0.124 +/- 0.05%) despite lower 25-OHD levels in Paget's patients. There was a significant inverse correlation between the severity of Paget's disease as measured by plasma alkaline phosphatase (AP) levels and 25-OHD levels (r = 0.392, p less than 0.02); however, 24,25-(OH)2D and 1,25-(OH)2D levels were not correlated with AP.(ABSTRACT TRUNCATED AT 250 WORDS)

Topics: 24,25-Dihydroxyvitamin D 3; Aged; Alkaline Phosphatase; Calcifediol; Calcitonin; Calcitriol; Calcium; Etidronic Acid; Humans; Middle Aged; Osteitis Deformans; Parathyroid Hormone; Vitamin D

Topics: 24,25-Dihydroxyvitamin D 3; Aged; Alkaline Phosphatase; Calcifediol; Calcitriol; Calcium; Creatinine; Dihydroxycholecalciferols; Female; Humans; Hydroxyproline; Intestinal Absorption; Male; Middle Aged; Osteitis Deformans

We have studied several biochemical indices of bone turnover and vitamin D metabolism in 32 untreated patients with Paget's disease and in 32 age-matched control subjects. patients with Paget's disease, as expected, were characterized by high bone turnover, as judged by alkaline phosphatase and urinary excretion of hydorxyproline. Serum values of 24,25-dihydroxyvitamin D3 (24,25(OH)2D3) and the ratio of 24,25(OH)2D3 to 25-OHD were significantly lower in patients than in control subjects. Serum concentrations of 1,25(OH)2D3 were normal in Paget's disease. The distribution of values for 24,25(OH)2D3 was log normal. On the basis of the normal range computed from control subjects, patients were divided into those with low or normal values for 24,25(OH)2D3. Disease activity, as judged by biochemical indices was significantly higher in the patients with the lower values of 24,25(OH)2D3. We conclude that Paget's disease is characterized by low circulating concentrations of 24,25(OH)2D3, particularly in patients with more extensive or severe disease.

Topics: 24,25-Dihydroxyvitamin D 3; Aged; Alkaline Phosphatase; Calcifediol; Calcitriol; Dihydroxycholecalciferols; Female; Humans; Hydroxyproline; Male; Middle Aged; Osteitis Deformans; Vitamin D